<DOC>
	<DOCNO>NCT02606214</DOCNO>
	<brief_summary>The objective study evaluate safety tolerability multiple dose TBA-354 healthy subject .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study With Dose Formulation Comparison Cohort Evaluate Safety , Tolerability , Pharmacokinetics TBA-354 Healthy Adult Subjects</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multiple ascend dose study conduct one study center United States . Three ( 3 ) multiple ascend dose cohort plan twelve ( 12 ) healthy subject ( 9 active 3 placebo ) cohort . There also dose formulation comparison cohort , enrollment six ( 6 ) subject plan . An additional multiple dose cohort twelve ( 12 ) subject may enrol . Safety assess throughout study ; serial ECGs serial blood sample collect safety pharmacokinetics ( PK ) assessment TBA‐354 . Dose escalation next cohort ( i.e. , dose level ) take place Sponsor , conjunction Principal Investigator , determine adequate safety , tolerability PK previous cohort demonstrate permit proceed next cohort . Upon review cohort data , Sponsor , conjunction Principal Investigator , may decide : 1 . Escalate dose plan . 2 . Evaluate intermediate dose level prior proceed next plan dose level concern arise PK safety warrant cease escalation . 3 . Repeat give dose level new cohort subject . 4 . Increase dose next cohort PK low expect previous cohort . 5 . Add cohort PK low expect cohort safety concern . 6 . Halt study . During dose escalation , time project Cmax individual exceed 7.6 µg/mL , high mean value no-observed-adverse-effect-level 3-month log toxicology study TBA 354 NCLN-103 . The predicted median Cmax final cohort exceed 3.2 µg/mL safety concern . Subjects Multiple Ascending Dose ( MAD ) Cohorts house Celerion clinic check-in Day 15 . Subjects return clinic day Day 16-Day 21 final one-week follow phone interview upon completion . Subjects Dose Formulation Cohort house Clerion clinic check-in Day 3 , visit clinic day Days 4-7 , house clinic Days 14-16 . Then subject return daily visit Days 17-20 , contact final one-week follow phone interview upon completion Day 28 .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>1 . Healthy adult male female nonchildbearing potential , 19 50 year age ( inclusive ) time screen . 2 . Body mass index ( BMI ) ≥ 18.5 ≤ 32.0 ( kg/m2 ) body weight less 50.0 kg . 3 . Medically healthy clinically significant screen result ( e.g. , laboratory profile , medical history , vital sign , ECGs , physical examination ) deem Investigator . 4 . No use tobacco nicotine containing product ( include smoke cessation product ) , minimum 6 month prior dose . 5 . Females nonchildbearing potential , undergone one follow sterilization procedure least 6 month prior dose : Hysteroscopic sterilization Bilateral tubal ligation bilateral salpingectomy Hysterectomy Bilateral oophorectomy postmenopausal amenorrhea least 1 year prior first dose serum follicle stimulate hormone ( FSH ) level consistent postmenopausal status screening . 6 . Nonvasectomized male ( male vasectomize less 120 day prior study start ) , must agree follow study participation 90 day follow last administration study drug : use condom spermicide engage sexual activity sexually abstinent donate sperm time . In event sexual partner surgically sterile , use condom spermicide necessary . None restriction list required vasectomized male whose procedure perform 120 day prior study start . 7 . Willing answer inclusion exclusion criterion questionnaire checkin . 8 . Subject understands study procedure provide write informed consent trial . 9 . Be able comply protocol assessment therein , include restriction . 1 . History presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease determine Investigator clinically relevant . 2 . History illness , opinion Investigator , might confound result study pose additional risk subject participation study . 3 . Surgery within past 90 day prior dose determine Investigator clinically relevant . 4 . History presence alcoholism drug abuse within past 2 year determine Investigator clinically relevant . 5 . Hypersensitive idiosyncratic reaction compound related TBA354 ( e.g. , nitroimidazoles metronidazole , etc. ) . 6 . Female subject pregnant lactating . 7 . Positive result urine drug/alcohol screen screen checkin . 8 . Positive urine cotinine screening . 9 . Serum magnesium potassium , calcium laboratory value outside normal range screening . 10 . Positive result screen Human Immunodeficiency Virus ( HIV ) , Hepatitis B Surface Antigen ( HBsAg ) , Hepatitis C antibody ( HCV ) . 11 . Seated blood pressure le 90/40 mmHg great 140/90 mmHg screening . 12 . Heart rate lower 40 bpm high 99 bpm screening . 13 . Any electrocardiogram abnormality Screening ( deem decision Investigator Sponsor 's Medical Monitor ) . NOTE : The follow consider clinically significant without consult Sponsor 's Medical Monitor : Mild first degree AV block ( PR interval &lt; 0.23 sec ) Right leave axis deviation Incomplete right bundle branch block Isolated leave anterior fascicular block ( leave anterior hemiblock ) young athletic subject 14 . QTcF interval &gt; 450 msec male &gt; 470 msec female screen , Day 2 , Day 1 , Day 1 ( predose ) , history prolong QT syndrome . 15 . Family history LongQT Syndrome sudden death without precede diagnosis condition could causative sudden death ( know coronary artery disease , congestive heart failure terminal cancer ) . 16 . History one combination , follow : Seizures seizure disorder Brain surgery . History head injury last five year Any serious disorder CNS relate neurological system , particularly one may lower seizure threshold . v. History seizures 17 . Use prescription medication within 14 day prior dose . 18 . Use overthecounter ( OTC ) medication , include herbal product vitamin , within 7 day prior dose , except acetaminophen . Up 3 gram per day acetaminophen allow discretion Investigator prior dose . 19 . Use drug substance know significant inhibitor Cytochrome P450 ( CYP ) enzymes and/or significant inhibitor substrates Pglycoprotein ( Pgp ) and/or Organic anion transport polypeptide ( OATP ) within 14 day prior first dose study drug . 20 . Use drug substance know inducer CYP enzymes and/or Pgp , include St. John 's Wort , within 28 day prior first dose study drug . 21 . Use drug substance know low seizure threshold . 22 . Blood donation significant blood loss within 56 day prior dose . 23 . Plasma donation within 7 day prior dose . 24 . Participation another clinical trial within 28 day prior dose . 25 . Prior treatment investigational product pretomanid OPC67683 . 26 . Consumption follow prior dose period : Alcohol 48 hour prior dose Grapefruit/Oranges 10 day prior dose Caffeine/Xanthine 24 hour prior dose</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>TBA-354</keyword>
	<keyword>Pulmonary Tuberculosis</keyword>
	<keyword>TB</keyword>
</DOC>